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Translocations involving *RUNX1* are known to decrease the function of the encoded protein in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) \[[@CR1]\]. For those involving chromosome 15, *SV2B* was the only *RUNX1* partner gene identified in AML \[[@CR2]\].

We report on two novel t(15;21) alterations leading to the concurrent disruption of *RUNX1* and *SIN3A* or *TCF12* (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Another interrupted gene is the *UBL7-AS1* long noncoding RNA gene.

In case 1, FISH experiments (Additional file [2](#MOESM2){ref-type="media"}: Table S2) mapped the breakpoint on der(21) within intron 7 of *RUNX1* (Additional file [3](#MOESM3){ref-type="media"}: Figure S1A-C). Moreover, SNP array analysis identified a 908-kb deletion near the 15q breakpoint on der(15) (Additional file [4](#MOESM4){ref-type="media"}: Table S3 and Additional file [3](#MOESM3){ref-type="media"}: Figure S1D-F). Genomic PCR revealed that intron 7 of *RUNX1* (chr21:36194775) was joined at intron 3 of *SIN3A* (chr15:75708434) (Fig. [1a](#Fig1){ref-type="fig"} and Additional file [5](#MOESM5){ref-type="media"}: Table S4) on der(21). Furthermore, intron 7 of *RUNX1* (chr21:36194861) was fused to the inverted sequence of *UBL7* (NM_032907.4) at intron 1 (chr15:74751664) on der(15), suggesting that a submicroscopic inversion accompanying the translocation led to the juxtaposition of *RUNX1* and *UBL7-AS1* with the same transcriptional orientation (Fig. [1a](#Fig1){ref-type="fig"}). ChimeraScan analysis of RNA-Seq data identified the fusion of *SIN3A* (exon 3; NM_015477) to *RUNX1* (exon 8; NM_001754) and of *RUNX1* (exon 7; NM_001754) to *UBL7-AS1* (intron 1; NR_038449.1). Both chimeric transcripts were validated by RT-PCR (Fig. [1b](#Fig1){ref-type="fig"} and Additional file [6](#MOESM6){ref-type="media"}: Table S5). In silico translation of the in-frame 5′-*SIN3A/*3′-*RUNX1* showed two ORFs of 171 and 163 amino acids, respectively, the first one retaining the transactivation domain of RUNX1 (Fig. [1c](#Fig1){ref-type="fig"}). The out-of-frame 5′-*RUNX1/*3′-*UBL7-AS1* encoded a protein of 373 amino acids, showing the substitution of RunxI with a GVQW putative binding domain (Fig. [1d](#Fig1){ref-type="fig"}). Thus, both chimeric *SIN3A*/*RUNX1* and *RUNX1*/*UBL7-AS1* encoded for truncated SIN3A and RUNX1 proteins. Interestingly, RT-qPCR revealed that the full-length *RUNX1* (NM_001754) and the 3′ portion of *SIN3A* (NM_015477) were downregulated (Fig. [1e](#Fig1){ref-type="fig"}), whereas *UBL7-AS1* was overexpressed (Additional file [7](#MOESM7){ref-type="media"}: Figure S2). Further, we evaluated the molecular impact of these fusion transcripts through a differential expression analysis, using the control datasets of 19 AML cases with normal karyotype from the The Cancer Genome Atlas data bank (<http://cancergenome.nih.gov/>). The results obtained by the QIAGEN's Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City) \[[@CR3]\], following the Partek Genomics Suite 6.6 (Partek Inc., St. Louis, MO, USA), indicated a significant number of differentially expressed genes within the AML pathway. The cell proliferation and myeloid differentiation pathways were significantly activated, whereas apoptosis exhibited reduced activity (Additional file [8](#MOESM8){ref-type="media"}: Figure S3 and Additional file [9](#MOESM9){ref-type="media"}: Table S6).Fig. 1t(15;21)(q24;q22) translocation in case 1. **a** *Genomic breakpoints on chromosomes 15 and 21 in case 1*: Top, schematic representation of wild-type chromosomes (black lines) and involved genes (exons are shown as rectangles and introns as lines connecting exons, with arrowheads indicating the direction of transcription). The dashed black lines indicate the breakpoints within all genes. Bottom, partial chromatograms indicate fusion sequences on der(15) (left) \[GenBank: KT336107\] and der(21) (right) \[GenBank: KT336106\]. The splicing event creating the runt-related transcription factor 1 (*RUNX1*)/*UBL7-AS1* fusion transcript is indicated in green. **b** RUNX1 *fusion transcripts*: reverse transcription polymerase chain reaction (RT-PCR) products corresponding to *SIN3A*/*RUNX1* \[GenBank: KT336104\] and *RUNX1*/*UBL7-AS1* \[GenBank: KT336105\] fusion transcripts (lanes 1 and 3, respectively) in case 1 are shown in the middle of the panel. Lanes 2 and 4: negative normal bone marrow samples. Lane 5: 2-log DNA ladder (New England Biolabs, Milan, Italy). Partial chromatograms (top) and structure (bottom) of *SIN3A*/*RUNX1* and *RUNX1*/*UBL7-AS1* PCR products are on the left and on the right, respectively. **c**, **d** *RUNX1 chimeric proteins*: both panels show in silico translation (ORFfinder and BlastP) of both wild-type and chimeric RUNX1 and SIN3A proteins. Arrows indicate the truncation breakpoints of wild-type proteins. **e** *Evaluation of* RUNX1 *and* SIN3A *expression levels in case 1:* exon-specific reverse transcription quantitative PCR analysis of *RUNX1* (left) and *SIN3A* (right) was performed in case 1 vs a control pooled sample of patients with acute myeloid leukemia. Asterisks indicate statistically significant results (*P* \< .05)

The results obtained in case 1 clearly suggest a role as a tumor suppressor (TS) gene not only for *RUNX1* (the shorter RUNX1 encoded by the chimeric *RUNX1*/*UBL7-AS1* should behave as a dominant negative mutant of the wild-type RUNX1), but also for *SIN3A.* We speculate that the inactivation of both proteins should have led to an abnormal activation of *RUNX1*/*SIN3A* target genes, leading to myelodysplasia. Even if haploinsufficiency was never reported for *SIN3A*, its role as a TS has been described in other tumors \[[@CR4]\]. Notably, the SIN3A corepressor was known to interact with RUNX1 \[[@CR5]\], leading to the transcriptional inactivation of their target genes \[[@CR6]\].

In cases 2 and 3, FISH indicated that *RUNX1* was interrupted within intron 7. Additionally, in case 4, a 600-kb deletion removed the 5′ portion of *RUNX1* starting from intron 6 (Fig. [2a](#Fig2){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Table S1). In all cases, *RUNX1* was joined with an opposite transcriptional orientation to intron 3 of *TCF12* (NM_003205), a basic helix-loop-helix transcription factor (Fig. [2b](#Fig2){ref-type="fig"}) fused with *MLL* in MDS \[[@CR7]\] and recurrently mutated in myeloproliferative disorders \[[@CR8]\]. Notably, in case 2, RT-qPCR indicated the downregulation of both *RUNX1* and *TCF12* (Fig. [2c](#Fig2){ref-type="fig"}) and IPA analysis disclosed significant deregulation of the AML pathway. The number of altered pathways was slightly higher than in case 1 (146 vs. 136) and mostly overlapped the previously described categories. Particularly, *RUNX1* was shown to control many differentially expressed genes involved in cell cycle regulation, inflammatory response, and transcription regulation (Additional file [8](#MOESM8){ref-type="media"}: Figure S3 and Additional file [9](#MOESM9){ref-type="media"}: Table S6).Fig. 2t(15;21)(q21;q22) translocation in cases 2, 3, and 4. **a**, **b** *Breakpoints on chromosomes 21 and 15*: partial karyotypes showing fluorescence in situ hybridization (FISH) results that allowed the mapping of t(15;21) translocation breakpoints on der(21) (a) and der(15) (b), using the consistently colored probes listed for cases 2 (first column) and 4 (second column). RP11-662O10 was used only in case 4. Cases 2 and 3 shared the same breakpoints (data not shown). On the right, the map of the BAC probes used in the FISH experiments, according to GRCh37/hg19, and identifying both translocation and deletion breakpoints, is shown. The black and orange dashed lines indicate the breakpoints in cases 2 and 4, respectively. The grey rectangle encompasses the deleted region flanking the translocation breakpoint in case 4. **c** *Evaluation of RUNX1 and TCF12 expression levels*: exon-specific reverse transcription quantitative polymerase chain reaction results of runt-related transcription factor 1 (*RUNX1*; left) and transcription factor 12 (*TCF12*; right) in case 2. Asterisks indicate statistically significant results (*P* \< .05)

We thus suggest a TS role for *TCF12* in myeloid disorders, as already described in colon carcinoma \[[@CR9]\]. The concurrent inactivation of *RUNX1* and *TCF12* should mimic the same leukemogenic effect of the t(8;21) RUNX1/CBFA2T1 fusion protein. E proteins, like TCF12, are inactivated through their interaction with the domain TAFH of CBFA2T1, leading to the inhibition of the p300/CBP histone acetyltransferase recruitment at their target genes' promoters and consequently to the lack of activation of genes with E-box promoters \[[@CR10]\].

To summarize, we here identified three novel *RUNX1* partner genes, including two transcription factors and a long noncoding RNA, in 2 t(15;21) translocations. Both of the t(15;21) translocations resulted in the concurrent inactivation of *RUNX1* and one related transcription factor (*SIN3A* or *TCF12*), leading to the potential haploinsufficiency of both involved genes. Moreover, the IPA analyses clearly indicated that the AML pathway was significantly deregulated in our samples, and showed that *RUNX1*, *SIN3A*, or *TCF12* have a crucial impact on differentially expressed genes. The analysis of additional cases harboring t(15;21) translocations will be helpful to better understand the pathogenetic impact of these alterations in myeloid neoplasms.
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